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Cognitive Performance and Mood Changes
in the Post-thyroidectomy Patient Treated with T4 versus T4+T3
Lorena Likaj, MPH
Abstract
This study investigated changes in cognition and mood
in the post-thyroidectomy patient. Specifically, this
study investigates changes in cognition and mood,
when the patient has been returned to normal,
laboratory serum thyroid-stimulating hormone (TSH)
reference levels, following conventional thyroid
hormone replacement therapies with levothyroxine
(T4) alone. Findings reveal a distinct, small, and
clinically significant subgroup of post-thyroidectomy
patients (10–15%) who continue to experience
impaired cognition and mood, even when routinely
measured serum TSH levels have been returned to
normal levels. Findings are discussed within a
conceptual matrix emphasizing the differential role of
deiodinase enzymes required for conversion of T4 to
T3 within the brain (Type II), compared to T4 to T3
conversion completed in peripheral tissues.
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Procedures
A systematic review of the professional medical
literature was used to summarize existing knowledge,
test specific research questions, and evaluate the
proposed model.
Seven studies, meeting specific inclusion and
exclusion criteria, were selected as representative of
all studies identified by the systematic review and are
presented here.

Findings

Purpose
The purpose of this study is to investigate changes in
mood and cognitive function in post thyroidectomy
patients. The reason this study is important is
because there are few studies that investigate
treatment of hypothyroidism in the post thyroidectomy
patient.

2. Can differences in the post-thyroidectomy patients,
who continue to experience impaired cognition and
mood, be explained by the hormone replacement
therapy intervention, T4 alone versus T4 in
combination with T3?
3. Does review, summary, and critical analysis of the
professional medical literature, from the period
1985- 2015, support a proposed new model,
emphasizing down regulation of deiodinase
enzymes type II in brain, as potentially causal in
explaining differences between post-thyroidectomy
patient who’s cognition and mood improves with
conventional hormone replacement therapies (8085%) and post-thyroidectomy patients, who fail to
demonstrate significant improvements in cognition
and mood?
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Conclusions
The use of T4 in combination with T3, in restoring
post-thyroidectomy patients to an euthyroid state, is
controversial among clinicians. Data from this review
reveal :
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2. Treatment with T4+T3 generates more favorable
results than treatment with T4 alone.
3. Data support the proposed model of down
regulation of deiodinase enzyme type II in brain, as
casual in explaining differences
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Figure 1. Percentage of patients evidencing no impairment and impaired cognition
or mood, following thyroidectomy, when serum thyroid values have been returned to
normal reference values. N = 397, Not impaired = 85%, Impaired = 15%, p < 0.05.
Original data extracted and reanalyzed from Bianco, A. and Casula, S. (2012).[1]
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Figure 2. Percentage of patients evidencing no impairment and impaired cognition
and mood, thyroidectomy, when serum thyroid values have been returned to normal
reference values. Not impaired = 90%, Impaired = 10%, p < 0.05. Original data
extracted and reanalyzed from Wiersinga (2014).[2]
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Of interest to us is the fact that, despite treatment and
achievement of euthyroid levels as measured by
routine plasma levels, 10-15 % of patients continue to
experience a decrease in cognitive function and
depression despite normal serum concentration of T4
and T3.

1. Do post-thyroidectomy patients, who have been
returned to normal thyroid stimulating hormone
levels, by way of conventional hormone
replacement therapies, continue to experience
impairments in cognition and mood?
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In these patients, the standard of treatment is daily
administration of levothyroxine, a synthetic form of
thyroxine (T4). The administration of T4 replaces the
low levels of T4 resulting from the surgical destruction
of the thyroid gland. The administered T4 is then
converted to T3 peripherally and in the brain through
the usual processes.
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Research Questions

This investigation is a systematic review of the
literature and limited only by the constraints of the
research design.

1. 10-15% of post-thyroidectomy patients evidence
impairment in cognition and mood, despite serum TSH
levels being returned to normal reference value levels
on T4 therapy alone.

Problem
Many patients with hypothyroidism, induced by a
complete thyroidectomy, develop depression,
decrease in cognitive function, and other psychiatric
symptoms. These symptoms are reversed with
thyroxine (T4) replacement therapy.

Limitations
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Figure 3. Correctly matched number and symbol - paired recall. Normal
performance is 6 or more, with a maximum possible score of 9. N = 15 women
patients with hypothyroidism, treated originally with T4 alone, and then treated with
T4 + T3. Original data extracted and reanalyzed from Bunevicius and Prange
(2000).[4] Paired t-test T4 with T4+ T3, p < 0.02.
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Figure 4. Beck Depression Inventory scores greater than 10 are associated with
impaired and depressed mood. N = 59 patients with autoimmune hypothyroidism on
stable T4 treatment times six months, and then treated with T4+T3. Randomized,
double blind. cross-over, experimental research design. Original data extracted and
reanalyzed from Nygaard, Jensen, Kvetny, et. al. (2009).[8] Paired t- test T4 with T4 +
T3, p < 0.01.
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Social Change Implications
This study proposes a new model, based upon down
regulation of enzymes responsible for the conversion
of T4 into T3. This model has the following social
change implications:
1. Improve the medical management of postthyroidectomy patients.
2. Improve the quality of life and standard of living of
post-thyroidectomy patients and their families.

